Who are Miretilan's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cleviprex, Sular, Procardia, Procardia, Isoptin, Cadral.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/endralazine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Miretilan — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Miretilan (ENDRALAZINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: endralazine. Area: Cardiovascular.

phase 2 endralazine Voltage-dependent L-type calcium channel subunit alpha-1C Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Miretilan (ENDRALAZINE). Miretilan works by blocking calcium channels in blood vessels, which helps to lower blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Miretilan TARGET	ENDRALAZINE		phase 2	endralazine	Voltage-dependent L-type calcium channel subunit alpha-1C
Cleviprex	CLEVIDIPINE	Chiesi	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1C	2008-01-01
Sular	NISOLDIPINE	Azurity	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1C	1995-01-01
Procardia	Nifedipine	Pfizer	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1C	1981-01-01
Procardia	NIFEDIPINE	Pfizer	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1C	1981-01-01
Isoptin	VERAPAMIL		marketed	Calcium Channel Blocker	Voltage-dependent L-type calcium channel subunit alpha-1C	1981-01-01
Cadral	CADRALAZINE		marketed	cadralazine	Myeloperoxidase, Voltage-dependent L-type calcium channel subunit alpha-1C

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (endralazine class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Miretilan — Competitive Intelligence Brief. https://druglandscape.com/ci/endralazine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing